Alex Goldberg

Starbucks Corporation (NASDAQ:SBUX) and Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 12/03/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Starbucks Corporation (NASDAQ:SBUX) and Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK).

Starbucks Corporation (NASDAQ:SBUX) a company that operates as a roaster, marketer, and retailer of specialty coffee worldwide closed down in its previous session (-0.48%) on 2,886,550 shares traded after Starbucks Said to Plan $750 Million Bond Sale After Settlement. Starbucks Corporation (NASDAQ:SBUX) is currently down (-1.93%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Starbucks Corporation (NASDAQ:SBUX)

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) a biopharmaceutical company that focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States closed up in its previous session (+6.60%) on 3,687,358 shares traded. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is currently up (+107.8%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com